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ABSTRACT The in vitro amplification of biologically im-
portant nucleic acids has proceeded principally by a strategy of
DNA replication. Polymerase chain reaction was the first such
protocol to achieve this goal. In this report, a transcription-
based amplification system (TAS) is described. Each cycle of
the TAS is composed of two steps. The first is a cDNA synthesis
step that produces one copy ofa double-stranded DNA template
for each copy of RNA or DNA target nucleic acid. During the
course of this cDNA synthesis step, a sequence recognized by a
DNA-dependent RNA polymerase is inserted into the cDNA
copy of the target sequence to be amplified. The second step is
the amplification of the target sequence by the transcription of
the cDNA template into multiple copies of RNA. This proce-
dure has been applied to the detection of human immunode-
ficiency virus type 1 (HIV-1)-infected cells. After four cycles of
TAS, the amplification of the vif region of the HIV-1 RNA
genome was measured to be, on the average, 38- to 47-fold per
cycle, resulting in a 2-5 x 106-fold increase in the copy number
of the original target sequence. This amplification by the TAS
protocol allows the detection of fewer than one HIV-1-infected
CEM cell in a population of 106 uninfected CEM cells.
Detection ofthe TAS-generated RNA from HIV-1-infected cells
can easily be accomplished by means of a bead-based sandwich
hybridization protocol, which provides additional specificity
for the identification of the amplified HIV-1-specific sequence.
The need to detect, identify, and subsequently isolate nucleic
acid molecules that are present in very small quantities has
long been a difficult problem for clinicians and molecular
biologists. An efficient solution to this problem has been
developed by the in vitro replication of specific segments of
the target nucleic acid of interest. Saiki et al. (1, 2) were the
first to describe a method to accomplish this task by the use
of repeated cycles of oligonucleotide primer-directed DNA
syntheses. This method (2), called polymerase chain reaction
(PCR), has successfully been employed to detect and clone
several genetic mutations, in such genes as f3-globin (1, 3),
factor VIII (4), HLA (5, 6), and dystrophin (7), as well as for
the forensic identification of individuals (8) and for detecting
specific translocation events characteristic of follicular lym-
phomas (9). In addition to genetic mutations, the detection
and identification of low-copy-number viruses, such as hu-
man immunodeficiency virus type 1 (HIV-1) (10) and human
T-cell leukemia virus type I (11, 12), have been reported after
the use of the PCR amplification protocol.
Enhancements of the PCR method have been reported,
including the use of thermal-stable DNA polymerase from
Thermus aquaticus (13, 14) and the addition of the recogni-
tion sequence from the T7 RNA polymerase to the oligonu-
cleotide primers, so that after multiple cycles of PCR, RNA
transcripts can be produced from the PCR-amplified DNA
(15, 16). In these enhancements of the PCR protocol, the
principal method of amplification relies on the use of DNA
replication of a defined region of the target sequence.
In this report, a transcription-based amplification system
(TAS) is described in which the production ofRNA copies of
the target sequence provides the principal means of in vitro
nucleic acid amplification. Using both HIV-1 RNA and
proviral DNA targets from HIV-1-infected cells, the effi-
ciency of the steps involved in the TAS protocol is described
quantitatively, and the manner in which the RNA products
are captured and detected using bead-bound oligonucleotides
(17, 18) is also illustrated.
MATERIALS AND METHODS
Materials. Uninfected and HIV-1-infected lymphocyte
cells (CEM) and plasmid pARV7A/2 containing a cDNA
copy of the HIV-1 genome inserted into the EcoRI site of
pUC19 (19) were obtained from D. Richman (University of
California, San Diego). Extractor columns were purchased
from Molecular Biosystems (San Diego, CA). Avian myelo-
blastosis virus reverse transcriptase (RT) was purchased
from Life Sciences (Saint Petersburg, FL). T7 RNA poly-
merase was purchased from Stratagene, Pharmacia, and New
England Biolabs. Oligonucleotides were synthesized by
phosphoramidite chemistry by using either an Applied Bio-
systems model 380A or a Biosearch model 3600 synthesizer.
The oligonucleotides used as primers and detection probes
are specific for HIV-1 and correspond to the sequences
reported by Ratner et al. (20) for the vif gene (21).
RNA Purification. HIV-1 RNA was extracted in total RNA
from HIV-1-infected CEM cells by the guanidinium isothio-
cyanate/cesium chloride gradient procedure (22).
HIV-1-Infected Sample Preparation. Uninfected CEM cells
or HIV-1-infected cells were pelleted by low-speed centrif-
ugation. The cell pellet was resuspended in 1 ml of 0.15 M
NaCl/10 mM Tris HCl, pH 7.5/50 mM EDTA/0.2% SDS/
proteinase K (1 mg/ml). After the lysate was Vortex mixed
vigorously, it was incubated at 50'C for 45 min with occa-
sional Vortex mixing. An Extractor column was used to
partially purify the nucleic acids. The lysate was loaded onto
a column equilibrated in 20 mM Tris-HCl (pH 7.5), and
unbound material was removed by washing the column with
4 ml of 0.3 M NaCl/20 mM Tris*HCI, pH 7.5. Total nucleic
acids were eluted from the column with 4 ml of0.5M NaCl/20
mM Tris*HCI, pH 7.5. After addition of 0.4 ml of 3 M sodium
acetate plus 100 ,ug of glycogen, the eluted nucleic acid was
precipitated with 2.5 vol of ethanol at -20'C for 2 or more hr.
Abbreviations: PCR, polymerase chain reaction; TAS, transcription-
based amplification system; HIV-1, human immunodeficiency virus
type 1; RT, reverse transcriptase; PBS, polymerase-binding sequence.
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The pelleted nucleic acid was resuspended in 10 mM
Tris HCl, pH 7.4/1 mM EDTA (TE) and further purified by
chromatography on a Sephadex G-50 spin column (22). The
eluted nucleic acids were precipitated with ethanol and
resuspended in TAS amplification buffer.
TAS. HIV-1 RNA or total extracted nucleic acid was
resuspended in a total volume of 100 ttl of TAS amplification
buffer (40mM Tris HCl, pH 8.1/8 mM MgCl2/25 mM NaCI/2
mM spermidine hydrochloride/5 mM dithiothreitol) contain-
ing bovine serum albumin at 80 gg/ml with 200 ,uM dATP,
200 ,uM dTTP, 200 /iM dGTP, 200 ,uM dCTP, 1 mM ATP, 1
mM GTP, 1 mM CTP, 1 mM UTP, and 0.25 Ag of HIV-1-
specific oligonucleotides 88-77 (5'-AATTTAATACGACTC-
ACTA TAGGGACACCTAGGGCTAACTATGTGTCC-
TAATAAGG-3') and 25 ,ug of 86-29 (5'-ACACCATATG-
TATGTTTCAGGGAAAGCTA-3'). [The italic portions of
oligonucleotides 88-77 and 87-263 refer to the T7 RNA
polymerase-binding sequence (PBS) and the preferred tran-
scriptional initiation site (23-26); the remainder of each
sequence represents the target-complementary sequence
(TCS), which targets each oligonucleotide.] The sample was
heated to 65°C for 1 min and annealed at 42°C for 1 min, after
which 10 units of avian myeloblastosis virus RT was added.
After a further 12-min incubation at 42°C, the sample was
heated at 100°C for 1 min and annealed at 42°C for 1 min, and
an additional 10 units of RT was added. The sample was
incubated for 12 min at 42°C. One hundred units of T7 RNA
polymerase was added, followed by a 25-min incubation at
37°C. Multiple cycles of TAS involved repeating the steps
above, except that the initial 1-min incubation at 65°C was
replaced with a 1-min denaturation step in subsequent cycles.
This protocol represents a TAS type I protocol. A modifi-
cation of this procedure has also been used, designated the
TAS type II protocol. The type II protocol differs after the
initial cDNA synthesis step (12 min at 42°C with RT); the
sample was denatured at 100°C for 1 min and annealed at 37°C
for 1 min, and 10 units of RT plus 100 units of T7 RNA
polymerase were added simultaneously. Incubation contin-
ued at 37°C for 30 min. Subsequent cycles were repeated from
the denaturation step. To detect the products of the TAS
reaction, aliquots were taken at various times and denatured
in 7.4% (vol/vol) formaldehyde/lOx SSC (21) at 55°C for 20
min. After chilling on ice, the samples were immobilized onto
a nitrocellulose membrane with the use of a slot-blot appa-
ratus (Schleicher & Schuell), and the nucleic acids were fixed
to the nitrocellulose by UV irradiation (27). The filters were
prehybridized at 55°C for 10 min in 0.5% bovine serum
albumin/0.5% polyvinyl pyrrolidone/5 x SSPE (22)/1% SDS
and then hybridized in the same buffer with oligonucleotide
probe 86-31 (5'-GCACACAAGTAGACCCTGAACTAGCA-
GACCA-3') or 86-32 (5'-TGGTCTGCTAGTTCAGGGTCT-
ACTTGTGTGC-3') at 2-5 x 106 cpm/ml, which are used as
detection probes for the negative and positive strands of the
amplified product, respectively. The filters were hybridized
for 1 hr at 55°C, then washed for three 5-min periods at room
temperature using 1x SSPE/1% SDS and washed once for 1
min at 55°C with the same buffer. The filters were autora-
diographed overnight at -70°C with one intensifying screen
on Kodak XAR film.
Bead-Based Sandwich Hybridization. Sephacryl beads con-
taining oligonucleotide 87-83 (5'-ATGCTAGATTGGTAA-
TAACAACATATT-3') were prepared as described (18). This
bead-bound oligonucleotide was used to capture the TAS-
amplified HIV-1 sequences after these targets had hybridized
to 32P-labeled detection oligonucleotide 86-31.
In a typical bead-based sandwich hybridization experi-
ment, the TAS-amplified target and 32P-labeled oligonucleo-
tide 86-31 were denatured in 10 ,l ofTE containing 0.2% SDS
at 650C for 5 min in an Eppendorf tube. To this, 10 tkl of a 2x
solution hybridization mixture [lOx SSPE/10% (wt/vol)
dextran sulfate] was added. The solution was mixed and
incubated at 420C for 2 hr.
Approximately 50 mg (wet weight) of Sephacryl beads was
prehybridized in 250 jul of hybridization solution (5x SSPE/1odextran sulfate/0.1% SDS) for 30 minat 370C. Immediately
prior to the capture step, the beads were centrifuged for 10 sec,
the prehybridization solution was removed, and 80 ,ul of fresh
hybridization solution was added, after which the hybridization
reaction mixture was transferred to the beads. The beads were
then incubated at 370C for 1 hr with occasional mixing.
After the bead hybridization step, the beads were centri-
fuged and the hybridization solution was transferred to a
scintillation counter vial. The beads were then washed five
times with 2x SSC at 370C. The first three washes were rapid;
1 ml of 2x SSC was added, and the beads were mixed well
and centrifuged 10 sec. For the final two washes, 1 ml of 2 x
SSC was added, and the beads were mixed and incubated at370C for 5 min before being centrifuged. Radioactivity of the
hybridization solution, each of the five washes, and beads
was measured by Cerenkov counting for 5-10 min. Scintil-
lation counter background was subtracted from all samples
(20-40 cpm). The percent target detected was calculated as
follows: [(cpm on beads/total cpm) x fmol of oligonucleo-
tide/fmol of target] x 100. The total cpm was the sum of the
cpm for the hybridization solution, five washes, and beads.
RESULTS
TAS Strategy and Efficiency of Amplification. Two cycles of
the TAS protocol are illustrated in Fig. 1. With either RNA
or DNA as the target sequences to be amplified, each cycle
is composed of a DNA synthesis and RNA transcription step.
During the cDNA synthesis part of a TAS cycle, short
nucleotide sequences recognized by a DNA-dependent RNA
polymerase (the PBSs) are positioned on the 3' side of the
region of the target sequence that is to be amplified. This is
accomplished through the use of an oligonucleotide primer
containing two domains. A target-complementary sequence
positions the PBS in the desired location prior to amplifica-
tion. This oligonucleotide (primer A) is employed in a primer-
extension reaction using RT or DNA polymerase, depending
upon the target sequences to be amplified. A second oligo-
nucleotide (primer B) is used in a similar primer-extension
reaction to make a double-stranded PBS-containing cDNA
copy of the target sequence (Fig. 1). Sequences recognized
by the RNA polymerases T7, T3, and SP6 can be employed
in the PBS domain, although the experiments described will
be limited to the use of the T7 RNA polymerase.
As indicated in Fig. 1, steps D-F, the RNA produced
during the first TAS cycle can serve as target sequences for
additional TAS cycles. Since DNA-dependent RNA tran-
scription can produce from 10 to 1000 RNA copies per DNA
template (24), only a few cycles of TAS are required to
achieve large-scale amplification of target nucleic acid se-
quences. Fig. 2A shows the amplification detected after one
cycle of TAS in which a 50-fold increase in the copy number
of the target RNA was achieved. This result emphasizes the
point that the amplification was achieved during the T7 RNA
polymerase transcription step and not through the cDNA
synthesis step. Interestingly, while the T7 RNA polymerase
is transcribing RNA copies of the target, the residual RT and
oligonucleotide primer B (Fig. 1, step D) are synthesizing a
cDNA copy of the amplified RNA transcript (Fig. 2A). It is
for this reason that oligonucleotide 86-32 can detect products
from the amplification, even though it is not complementary
to the RNA product produced by the T7 RNA polymerase. If
the RT was inactivated (by heating to 65°C for 5 min) prior to
the transcription step in a TAS cycle, only the hybridization
to the original target RNA and first-strand cDNA was
observed with oligonucleotide probe 86-32 (Fig. 2B); how-
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FIG. 1. TAS. A two-cycle scheme for amplifying an RNA target
sequence (- - -) using sequential cDNA synthesis and RNA transcrip-
tion is displayed as seven steps. A target nucleic acid molecule RNA (or
denatured DNA) is hybridized to a primer oligonucleotide (primer A)
that contains a PBS (for T7, T3, or SP6 polymerase) and a target-
complementary sequence (TCS) (step A). RT elongates primer A to
yield a newly synthesized DNA strand complementary to the target
RNA (step B). The RNADNA heteroduplex is denatured by heat (A)
and oligonucleotide B is annealed to the newly synthesized DNA strand
containing the PBS. RT is added to produce a double-stranded cDNA
and a new DNA-RNA heteroduplex (step C). Incubation of the double-
stranded cDNA with T7 (T3 or SP6) RNA polymerase results in the
synthesis of multiple RNA transcripts from the PBS-containing double-
stranded DNA template (step D). Some of this RNA is immediately
converted to RNA-DNA heteroduplex by RT (still in the reaction
mixture from step C) using oligonucleotide B as a primer. Further
amplification of target sequences can be obtained by a second cycle of
cDNA synthesis (steps E and F) and RNA transcription (step G).
ever, the TAS-generated RNA product was observed with
oligonucleotide probe 86-31.
Probe a3; a-
FIG. 2. (A) Detection of products in a single-cycle TAS reaction.
HIV-1 RNA (10 fmol) was amplified in a single cycle of a TAS type
I reaction. Oligonucleotides 88-77 and 86-29 were used as primers.
Two samples (each 5% of the total reaction mixture) were taken prior
to amplification (target), after the cDNA synthesis step (Fig. 1, step
C) (cDNA), or after the transcription step (Fig. 1, step D) (TAS
product). The nitrocellulose-immobilized samples were hybridized
to 32P-labeled oligonucleotide 86-32 or 86-31. Oligonucleotide 86-31
detects the first-strand cDNA product as well as the amplified RNA
transcript made by the T7 polymerase. Oligonucleotide 86-32 detects
the target HIV-1 RNA, the second-strand cDNA product, and the
first-strand cDNA product made from the RNA transcript synthe-
sized by T7 RNA polymerase. In this instance, the specific activity
of probe 86-31 is 2 times lower than the specific activity of probe
86-32, as determined using pARV7A/2 as a control on the filters (data
not shown). (B) Detection of DNA synthesis by RT during the
transcription step in a TAS protocol. Two reactions using HIV-1
RNA (10 fmol) as target were amplified in one cycle of a TAS type
I protocol using oligonucleotides 88-77 and 86-29 as primers. Prior to
the addition of the T7 RNA polymerase (i.e., prior to Fig. 1, step D),
one reaction was heated to 650C for 5 min to inactivate the RT.
Samples (5% ofthe total volume) ofeach reaction mixture were taken
prior to amplification (target) or after amplification (TAS products).
With four cycles of TAS, following a type I protocol, a 2-
5 x 106 amplification was obtained, with an average increase
of 38- to 47-fold per TAS cycle (Fig. 3). However, modifi-
cations of the type I TAS protocol were made based on the
observations that the RT remained active during the T7 RNA
polymerase transcription step (Fig. 1, step D) and that the
cDNA primed from oligonucleotide B could efficiently be
used to prime a fill-in reaction of the promoter binding site on
primer A (Fig. 1, step E). The protocol modification, de-
scribed as type II TAS, eliminates one of the RT synthesis
steps after the initial RT step (in a multiple-cycle reaction);
RT and T7 RNA polymerase are added simultaneously after
the initial RT step. Fig. 3B shows the efficiency of the type
II protocol per cycle over a total of six cycles. After six
cycles, a 2 x 106-fold amplification was obtained, giving an
average amplification of 11- to 13-fold per cycle. Measured on
a per-cycle basis, the amount of amplification decreased as
the number of cycles increased (by the sixth cycle, only a
2-fold amplification was observed). Although these modifi-
cations lower the efficiency ofTAS per cycle, the number of
manipulations and time required per cycle are reduced,
thereby allowing more cycles to be done in a shorter time.
Four cycles of the type I TAS protocol require 4 hr, whereas
six cycles of the type II protocol require only 3.25 hr.
Sensitivity in Detecting HIV1--Infected Cells. Harper et al.
(28) have reported that only 1 in 104 or 105 peripheral blood
lymphocytes appears to be infected with HIV-1. This implies
that in a 1-ml sample of whole blood, only 1-100 HIV-
1-infected cells are present in the 106 lymphocytes isolated.
The detection with TAS of the vifregion of HIV-1 present in
fewer than one HIV-1-infected cell equivalent in a total
population of 106 uninfected lymphocytes is demonstrated in
Fig. 4. Only 25% of the total nucleic acid extracted from each
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FIG. 3. (A) Efficiency of amplification per cycle in four cycles of a type I TAS protocol. HIV-1 RNA (10 amol) was used as target in a
four-cycle TAS type I amplification reaction using priming oligonucleotides 88-77 and 86-29. Samples (5% of the total reaction mixture) were
taken after each cycle of TAS, diluted as necessary, denatured, and immobilized onto nitrocellulose. The filter was hybridized to 32P-labeled
oligonucleotide 86-31, which detects the amplified product RNA made from the T7 promoter. As controls, both pARV7A/2 plasmid DNA
(full-length HIV-1 cDNA inserted into the EcoRI site of the pUC19 vector) and HIV-1 RNA were blotted and hybridized to probes 86-31 and
86-32, respectively, to allow calculation of the overall amplification. (B) Efficiency of amplification per cycle in six cycles of a type II TAS
protocol. Purified HIV-1 RNA (10 amol) was used as target in a six-cycle TAS type II amplification reaction using priming oligonucleotides 88-77
and 86-29. Samples (5% of the total reaction mixture) were taken after each cycle of TAS, diluted as necessary, denatured, and slot-blotted to
nitrocellulose. The filter was hybridized to 32P-labeled oligonucleotide 86-31, which detects the amplified product RNA made from the T7
promoter. As controls, both pARV7A/2 plasmid DNA and HIV-1 RNA were blotted and hybridized to probes 86-31 and 86-32, respectively,
to allow calculation of the overall amplification.
dilution was employed for amplification, and only 5% of the
amplification reaction was used for the hybridization analy-
sis. With a simple slot-blot assay, it was possible to detect
above background the HIV-1 sequence from less than one
HIV-1-infected CEM cell equivalent.
Detection of TAS-Generated, HIV-1-Specific RNA by Sand-
wich Hybridization Using OligoBeads. The problems associ-
ated with the use of nitrocellulose and nylon membranes as
supports for hybridizations have been studied (17). The
ability to carry out quasi-homogeneous hybridizations (i.e.,
near solution-like hybridization conditions) by using bead-
bound oligonucleotides as a hybridization matrix has permit-
ted the rapid detection of the TAS-amplified HIV-1 RNA
product. RNA produced by TAS amplification from a dilution
of HIV-1-infected cells was captured and detected with a
straightforward sandwich hybridization format (Fig. 5 and
Table 1). Each sandwich hybridization was conducted by first
hybridizing the amplified RNA to an excess of 32P-labeled
detection oligonucleotide (86-31). This RNA-DNA hybrid
4
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32. The signals for each infected
0 infected cells
cell sample shown represent 1.25%
of the total extracted nucleic acid
10 [i.e., 1.25% of 10i, 102, 10, and 1
10 -2 HIV-1-infected CEM cell(s)].
was captured by a second oligonucleotide probe (86-83) that
was tethered by its 5' end to the surface of a Sephacryl bead
(OligoBead). The percent of the 32P-label associated with the
beads allows a calculation of the number of fmol of target
detected by sandwich hybridization. As indicated in Fig. 5
and Table 1, this hybridization format is capable of quanti-
tatively detecting the presence of HIV-1 sequences in in-
fected cells over two orders of magnitude by using only a
small portion of the TAS amplification reaction mixture.
Considering the results ofthis experiment, several interesting
features of this method of detection merit notice. (i) The
results from duplicate experiments indicate close reproduc-
ibility of the assay. (it) The levels of sensitivity of this de-
tection method are underscored by the need to use only a
small quantity (i.e., >1 4l of the 140-,41 volume) of the am-
plification reaction mixture. (iii) It is possible to distinguish
HIV-1 sequences present in 25% of a sample derived from 1
infected cell in a population of 106 uninfected cells.
DISCUSSION
The utility of in vitro target amplification, accomplished
principally through cycles of DNA replication, has been
demonstrated by the application of PCR to a variety of
cloning and diagnostic uses. This report focuses on TAS as
a means of achieving the same goals. This alternative method
provides several distinct features not associated with the
PCR protocol. (i) Because of the inherent property of RNA
polymerases to produce 10-103 copies of RNA per copy of
DNA template, fewer cycles of amplification are required to
achieve large increases in the copy number (106 copies in four
cycles). As a consequence, fewer thermal denaturation steps
are required, thus simplifying the overall protocol. (it) Since
the product of the TAS protocol is in part single-stranded
RNA, it can be detected without the need for denaturation
prior to detection by hybridization. The utility of such RNA
products as templates for sequencing using the dideoxy
chain-termination method has been demonstrated (16, 29).
Detection and positive identification of the TAS-generated
RNA by OligoBeads with a sandwich hybridization protocol
provide an added level of specificity to the amplification
reactions. As described, the detection of PCR-amplified
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FIG. 5. Bead-based sandwich hybridization protocol used to
detect TAS-amplified HIV-1 sequences. Sandwich hybridization
reactions were carried out by using 50mg (wet weight) of OligoBeads
containing end-attached capture oligonucleotide 87-83 and 20 fmol of
32P-labeled detection oligonucleotide per reaction mixture. The
HIV-1 sequences present in each dilution [from 103 to 1 HIV-1 CEM
infected cell(s) per 106 cells] were amplified by the TAS protocol.
Volumes of the amplification reaction mixture from 0.016 to 0.3 IAI
(from a total 140 IL) were used in the sandwich hybridization reaction
mixture. The logarithms of the number of HIV-1 sequences detected
(fmol/,kl) and the number of HIV-1-infected cells are plotted.
DNA fragments has most routinely been accomplished by
either standard Southern hybridization methods (9, 13) or by
the solution hybridization with a 32P-labeled oligonucleotide,
followed by gel electrophoresis (10). In the use of the TAS
and bead-based sandwich hybridization approaches, positive
identification of the presence of the target sequence of
interest depends upon (i) oligonucleotide primer-directed
transcription of a specific region of interest, (ii) hybridization
of TAS-generated RNA by a specific detection oligonucleo-
tide, and (iii) a capture hybridization of the amplified
RNA-detection oligonucleotide complex. This combination
of the TAS and OligoBead detection protocols decreases the
probability of detecting partially homologous but nonspecific
target sequences in a complex biological sample.
The time required to carry out each cDNA and transcription
step in a single cycle of TAS is 24 and 25 min, respectively.
Consequently, four cycles of TAS can be accomplished in <4
hr. The detection of TAS-generated RNA by sandwich hybrid-
ization requires a subsequent 4 hr. This mode of detection
eliminates the need for autoradiography.
The ability to amplify and quantitate biologically important
but rare nucleic acid molecules provides the tools to carry out
studies hitherto unapproachable. Natural history studies
focusing on the levels of HIV-1 present during various
clinical stages of the disease process or drug efficacy studies
Table 1. Bead-based sandwich hybridization detection of
TAS-amplified HIV-1 sequences
Vol. of
HIV-1 reaction Bead- % of HIV-1
target mixture Total bound detection sequences
sequences, amplified, cpm cpm probe on detected,
no. ,p1 (x 10-2) (X 10-2) beads fmol/pi
0.016 857.3 41.1 4.8 53
869.9 40.1 4.7
102 0.033 876.4 23.9 2.7 13.6
761.9 21.6 2.8
10 0.33 770.1 19.1 2.5 1.2
776.4 18.3 2.4
1 0.33 790.1 9.2 1.2 0.4
898.7 10.1 1.1
0 0.33 939.0 4.9 0.5
913.4 5.0 0.5
that require quantitative measurements of levels of HIV-1
before and after therapy are only two of the areas that can be
investigated using straightforward amplification and hybrid-
ization technologies.
We thank Dr. Douglas Richman for supplying the HIV-1-infected
and uninfected CEM cells and the pARV7A/2 plasmid; Dr. U.
Merten for his conceptual contribution to this procedure; Drs. G.
Wahl and L. Orgel for their helpful discussions; Drs. T. J. Kwoh and
J. Guatelli for comments upon reading the manuscript; L. Blonski for
her assistance in the synthesis of the oligonucleotides; and J. Doty
for her assistance in the preparation of this manuscript. The tests of
the procedure on HIV-1-infected cells were partially supported by a
subcontract from the National Heart, Lung, and Blood Institute
(NO1-HB-6-7019).
1. Saiki, R. K., Scharf, S., Faloona, F., Mullis, K. B., Horn, G. T.,
Erlich, H. A. & Arnheim, N. (1985) Science 230, 1350-1354.
2. Mullis, K. B. & Faloona, F. (1987) Methods Enzymol. 155, 335-350.
3. Embury, S. H., Scharf, S. J., Saiki, R. K., Gholson, M. A., Gol-
bus, M., Arnheim, N. & Erlich, H. A. (1987) N. Engl. J. Med. 316,
656-661.
4. Kogan, S. C., Doherty, M. & Gitschier, J. (1987) N. Engl. J. Med.
317, 985-990.
5. Erlich, H. A., Sheldon, E. L. & Horn, G. (1986) BiolTechnology 4,
975-981.
6. Saiki, R. K., Bugawan, T. L., Horn, G. T., Mullis, K. B. & Erlich,
H. A. (1986) Nature (London) 324, 163-166.
7. Chelly, J., Kaplan, J.-C., Maire, P., Gautron, S. & Kahn, A. (1988)
Nature (London) 333, 858-860.
8. Higuchi, R., von Beroldingen, C. H., Sensabaugh, G. F. & Erlich,
H. A. (1988) Nature (London) 332, 543-546.
9. Lee, M.-S., Chang, K.-S., Cabanillas, F., Freireich, E. J., Trujillo,
J. M. & Stass, S. A. (1987) Science 237, 175-178.
10. Kwok, S., Mack, D. H., Mullis, K. B., Poiesz, B., Ehrlich, G.,
Blair, D., Friedman-Kien, A. & Sninsky, J. J. (1987) J. Virol. 61,
1690-1694.
11. Duggan, D. B., Ehrlich, G. D., Davey, F. P., Kwok, S., Sninsky,
J., Goldberg, J., Baltrucki, L. & Poiesz, B. J. (1988) Blood71, 1027-
1032.
12. Bhagavati, S., Ehrlich, G., Kula, R. W., Kwok, S., Sninsky, J.,
Udani, V. & Poiesz, B. J. (1988) N. Engl. J. Med. 318, 1141-1144.
13. Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R.,
Horn, G. T., Mullis, K. B. & Erlich, H. A. (1988) Science 239,487-
491.
14. Erlich, H. A., Gelfand, D. H. & Saiki, R. K. (1988) Nature
(London) 331, 461-462.
15. Murakawa, G. J., Zaia, J. A., Spallone, P. A., Stephens, D. A.,
Kaplan, B. E., Wallace, R. B. & Rossi, J. J. (1988) DNA 7, 287-295.
16. Stoflet, E. S., Koeberl, D. D., Sarkar, G. & Sommer, S. S. (1988)
Science 239, 491-494.
17. Gingeras, T. R., Kwoh, D. Y. & Davis, G. R. (1987) Nucleic Acids
Res. 15, 5373-5389.
18. Ghosh, S. S. & Musso, G. F. (1987) Nucleic Acids Res. 15, 5353-
5372.
19. Luciw, P. A., Potter, S. J., Steimer, K. & Dina, D. (1984) Nature
(London) 312, 760-763.
20. Ratner, L., Haseltine, W., Patarca, R., Livak, K. J., Starcich, B.,
Josephs, S. F., Doran, E. R., Rafalski, J. A., Whitehorn, E. A.,
Baumeister, K., Ivanoff, L., Petteway, S. R., Pearson, M. L.,
Lautenberger, J. A., Papas, T. S., Ghrayeb, J., Chang, N. T.,
Gallo, R. C. & Wong-Staal, F. (1985) Nature (London) 313, 277-
284.
21. Gallo, R., Wong-Staal, F., Montagnier, L., Haseltine, W. A. &
Yoshida, M. (1988) Nature (London) 333, 504-505.
22. Maniatis, T., Fritsch, E. F. & Sambrook, J. (1982) Molecular
Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory,
Cold Spring Harbor, NY).
23. Brown, J. E., Klement, J. F. & McAllister, W. T. (1986) Nucleic
Acids Res. 14, 3521-3526.
24. Dunn, J. J. & Studier, F. W. (1983) J. Mol. Biol. 166, 477-535.
25. McGraw, N. J., Bailey, J. N., Cleaves, G. R., Dembinksi, D. R.,
Gocki, C. R., Jollitte, L. K., MacWright, R. S. & McAllister, W. T.
(1985) Nucleic Acids Res. 13, 6753-6766.
26. Milligan, J. F., Groebe, D. R., Witherell, G. W. & Uhlenbeck,
0. C. (1987) Nucleic Acids Res. 15, 8783-8798.
27. Church, G. M. & Gilbert, W. (1984) Proc. Natl. Acad. Sci. USA 81,
1991-1995.
28. Harper, M. E., Marselle, L. M., Gallo, R. C. & Wong-Staal, F.
(1986) Proc. Natl. Acad. Sci. USA 83, 772-776.
29. Sarkar, G. & Sommer, S. S. (1988) Nucleic Acids Res. 16, 5197.
Biochemistry: Kwoh et al.
